The role of non-neutralising ADCC antibodies in the treatment of human influenza B virus (IBV) infection with anti-influenza hyperimmune immunoglobulin (Flu-IVIG) (Old ID 26827)

The University of New South Wales
Hillary Vanderven
Role

Principal Investigator

Description

Antibody-dependent cellular cytotoxicity (ADCC) and other Fc-mediated antibody functions are increasingly recognised as potential mediators of influenza immunity. However, a definitive role for ADCC antibodies during severe human influenza infection remains unclear. The INSIGHT006 study (NCT02287467) provides a unique platform to examine the impact of neutralising and non-neutralising ADCC antibodies, delivered by Flu-IVIG, on outcomes of severe human influenza.

Date

01 May 2020 - 30 Apr 2021

Project Type

CONTRACT_RESEARCH

Keywords

Antibody;Antibody-Dependent Cellular Cytotoxicity;Natural Killer Cells;Antibody Dependent Phagocytosis;Influenza

Funding Body

The University of New South Wales

Amount

100000

Project Team

N/A